Efficacy and Safety of Folisurge, a Biosimilar Recombinant Follicle-Stimulating Hormone, Versus Gonal-F in Assisted Reproductive Technology Practice in India: A Real-World Study
Folisurge was comparable to Gonal-f in terms of serum β-hCG positive rate. The higher yield of oocytes and embryos in the Folisurge group should be interpreted in the context of its higher baseline AFC, which may have influenced these results. No major safety concerns were observed.
Authors
- J. Panday
- Nitasha Gupta (ORCID: https://orcid.org/0000-0003-4337-2368)
- Walmik Mistari (ORCID: https://orcid.org/0000-0001-6296-4196)
- Isha Suwalka (ORCID: https://orcid.org/0000-0001-8340-5967)
- Nihar Ranjan Bhoi (ORCID: https://orcid.org/0000-0002-2238-2033)
- Sara Zaidi (ORCID: https://orcid.org/0000-0002-9980-6826)
- Ritu Punhani (ORCID: https://orcid.org/0000-0001-6107-911X)
- Nihita Pandey
- Shipra Nigam
- V Chandra (ORCID: https://orcid.org/0000-0003-2288-2481)
- Shashank Sanagoudar
- Anjali Gahalan
Institutions
- Indira Gandhi Memorial Hospital (MV)
- Indra (Spain) (ES)
- EFD Induction (Germany) (DE)
- Indira Gandhi Delhi Technical University for Women (IN)
Publication Details
- Journal
- Cureus
- Published
- 2025-12-07
- DOI
- https://doi.org/10.7759/cureus.98622
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00